Theravance Stock Plummets 29% on Drug Trial Failure

Key Developments

Theravance Biopharma's stock (NASDAQ:TBPH) dropped by 29% following the failure of its Phase 3 CYPRESS study for ampreloxetine. The drug did not meet its primary endpoint for treating symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy.

Company's Strategic Response

In response, the company has discontinued the ampreloxetine program. Its Strategic Review Committee is accelerating an evaluation of strategic options, including a potential sale of the company. A major organizational restructuring is also underway, targeting a 60% cost reduction, or approximately $70 million, which will affect about 50% of its workforce.

Financial Standing and Outlook

Despite the setback, Theravance reported that its COPD treatment, YUPELRI, achieved U.S. net sales of $266.6 million in fiscal 2025, a 12% year-over-year increase. The company maintained a strong cash position of $326.5 million as of December 31, 2025, with no debt.

Summary

While the trial failure was a significant blow to Theravance's stock, the company is implementing drastic measures to preserve shareholder value through major cost-cutting and exploring a potential sale. The performance of YUPELRI provides a stable revenue stream during this transition.

FAQ

Q: Why did Theravance Biopharma's stock price fall?
A: The stock fell 29% after its Phase 3 clinical trial for the drug ampreloxetine failed to meet its primary endpoint.

Q: What is the company doing in response to the trial failure?
A: Theravance is discontinuing the drug program, restructuring to cut costs by 60%, and exploring a potential company sale.

Source: Investing.com